KemPharm is planning to initiate the development of KP511, an oral prodrug of hydromorphone that is used to manage pain in patients where an opioid analgesic is appropriate.

The drug candidate, which was identified using the Ligand Activated Therapy (LAT) approach, is the second product in the company’s pain therapy range.

KP511 has demonstrated superior pharmacological characteristics, an improved safety profile and reduced symptoms of constipation, and has limited abuse potential in preclinical studies.

The drug candidate also has tamper-resistant properties, the company said.

KemPharm CEO Travis Mickle said the company aims to develop prescription options to enable physicians to treat pain without the liabilities of drug abuse and diversion or the negative side effect of constipation, which is typically associated with opioids.


How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.